Get the Stockscreener App
26.43
1.97%
-0.53
Pre-market:
26.67
0.24
+0.91%
Viking Therapeutics Inc stock is traded at $26.43, with a volume of 2.25M.
It is down -1.97% in the last 24 hours and down -7.03% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$26.96
Open:
$26.69
24h Volume:
2.25M
Relative Volume:
0.61
Market Cap:
$3.27B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-28.42
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-9.30%
1M Performance:
-7.03%
6M Performance:
-43.40%
1Y Performance:
-49.19%
1-Day Range:
$26.00
$27.01
1-Week Range:
$25.61
$30.17
52-Week Range:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
26.43 | 3.27B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
(VKTX) Proactive Strategies - news.stocktradersdaily.com
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200% - TipRanks
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - MSN
Viking Therapeutics (VKTX) Rises on Expected Developments - MSN
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely - Yahoo Finance
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Investors Are Gobbling Up Shares of These 10 Firms - Insider Monkey
Viking Therapeutics (VKTX) to Participate in B. Riley's Montreal Meeting | VKTX Stock News - GuruFocus
Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)? - MSN
Jim Cramer Nailed These 11 Stock Predictions - Insider Monkey
1 Stock Down 34% This Year to Buy and Hold - AOL.com
Transcript : Viking Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 11 - marketscreener.com
July 25th Options Now Available For Viking Therapeutics (VKTX) - Nasdaq
(VKTX) Investment Analysis - news.stocktradersdaily.com
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - sharewise
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
Could Viking Therapeutics Become the Next Eli Lilly? - The Globe and Mail
3 Best Growth Stocks to Buy in June - The Motley Fool
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside? - MSN
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
SA analyst upgrades: NVDA, DJT, VKTX, BRK.A, BEAM (NVDA:NASDAQ) - Seeking Alpha
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade) - Seeking Alpha
Viking Therapeutics to Participate at Upcoming Investor Conferen - GuruFocus
Viking Therapeutics to Participate at Upcoming Investor Conferences | VKTX Stock News - GuruFocus
Viking Therapeutics to Participate at Upcoming Investor Conferences – Company Announcement - Financial Times
Viking Therapeutics Lines Up Presentations at Goldman Sachs, William Blair Healthcare Conferences - Stock Titan
Viking Therapeutics Holds Annual Stockholders Meeting - TipRanks
Viking Therapeutics: Buy It For The Future And Ignore The Noise (NASDAQ:VKTX) - Seeking Alpha
(VKTX) On The My Stocks Page - news.stocktradersdaily.com
Better Weight Loss Stock: Amgen or Viking Therapeutics? - MSN
Viking Therapeutics: Weight-Loss Story Remains Intact (NASDAQ:VKTX) - Seeking Alpha
Bank of America Corp DE Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics: Near-Term Catalysts And Competitor Readouts - Seeking Alpha
BNP Paribas Financial Markets Has $1.88 Million Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Viking Therapeutics (VKTX) Stock Rises Amid Novo Nordisk CEO Cha - GuruFocus
Why Viking Therapeutics Stock Bumped 3% Higher Today - Mitrade
When (VKTX) Moves Investors should Listen - news.stocktradersdaily.com
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):